AC
SCNI

Armistice Capital’s Scinai Immunotherapeutics SCNI Stock Holding History

Armistice Capital’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.08K Buy
+3,594
New +$17.7K ﹤0.01% 328
2024
Q2 		– Sell
-1,218
Closed -$63.2K – 364
2024
Q1 		$63.2K Sell
1,218
-1,091
-47% -$56.3K ﹤0.01% 313
2023
Q4 		$137K Sell
2,309
-1,315
-36% -$90.4K ﹤0.01% 250
2023
Q3 		$315K Buy
+3,624
New +$464K ﹤0.01% 180

Other funds holding SCNI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital's SCNI Position: Q2 2026 in Review

Armistice Capital opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 3,594 shares worth $9.08K. The stake represents ﹤0.01% of the portfolio and ranks #328 among its holdings. This is a return to the name: Armistice Capital previously reported a position in SCNI as recently as Q1 2024.

Armistice Capital first reported a position in SCNI in Q3 2023 and has held it in 4 quarters since. The position peaked at $315K in Q3 2023. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • Armistice Capital held 3,594 shares of Scinai Immunotherapeutics worth $9.08K as of Q2 2026.
  • Scinai Immunotherapeutics was a new Armistice Capital position in Q2 2026.
  • Scinai Immunotherapeutics made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #328 holding.
  • Armistice Capital first reported a position in Scinai Immunotherapeutics in Q3 2023 and has held it in 4 quarters since.
  • Armistice Capital's Scinai Immunotherapeutics position peaked at $315K in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.